8-Oxo-guanine DNA damage induces transcription errors by escaping two distinct fidelity control checkpoints of RNA polymerase II
To view or add a comment, sign in Samjin Pharmaceutical applies for domestic Phase 1 clinical trials of novel inflammation and immunology drug candidate SJN314 Samjin Pharmaceutical (hereinafter referred to as Samjin Pharm) announced on February 4 that it has submitted an Investigational New Drug (IND) application to the Ministry of Food and Drug Safety (MFDS) for a Phase 1 clinical trial of SJN314 (development code). The candidate represents a key asset within the company's novel drug research pipeline focused on Inflammation & Immunology. SJN314 is an orally administered, small-molecule inhibitor of Mas-related G-protein-coupled receptor X2 (MRGPRX2), being developed for the treatment of inflammatory conditions such as chronic spontaneous urticaria (CSUR) and atopic dermatitis
Endometriomas These cysts are a result of the tissue that normally grows inside the uterus to develop on the outside of the uterus which then attaches to the ovaries
Over months, patterns emerge that short-term tracking cannot reveal
Why does creating a website for a semaglutide weight loss company cost so much
In line with this, by using whole-exome sequencing on diffuse large B-cell lymphoma patients, a loss of the chromosomic region including CT2 gene in half of the patients has been shown
